Navigation Links
Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019
Date:5/15/2012

313.6 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -the UK 323.7 Neuroendocrine Carcinoma Therapeutics Market Size (2005-2010)- France 333.8 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) - France 343.9 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) - Germany 353.10 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -Germany 363.11 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) - Italy 373.12 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -Italy 383.13 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) - Spain 393.14 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) - Spain 403.15 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) – Japan 413.16 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) - Japan 423.17 Drivers and Barriers for Neuroendocrine Carcinoma Therapeutics Market 433.17.1 Drivers for the Neuroendocrine Carcinoma Therapeutics Market 433.17.2 Barriers for the Neuroendocrine Carcinoma Therapeutics Market 433.18 Key Events Impacting the Future Market 443.19 Opportunity and Unmet Need 443.19.1 Gastrointestinal carcinoid (NETs) 453.19.2 Pancreatic NETs 453.20 Key Takeaway 464 Neuroendocrine Carcinoma Therapeutics Market- Competitive Assessment 474.1 Overview 474.1.1 Strategic Competitor Assessment 474.2 Product Profiles for the Major Marketed Products in Neuroendocrine Carcinoma 494.2.1 Afinitor (everolimus, RAD001) 494.2.2 Sutent (sunitinib) 504.2.3 Sandostatin LAR (octreotide acetate) 514.3 Key Takeaway 515 Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment 525.1 Overview 525.2 Strategic Pipeline Assessment 525.3 Analysis by Phase of Development 535.3.1 Neuroendocrine Carcinoma Therapeutics - Phase III Pipeline 535.3.2 Neuroendocrine Carcinoma Therapeutics - Phase II Pipeline 545.3.3 Neuroendocrine Carcinoma Therapeutics- Phase I Pipeline 545.3.4 Neuroendocrine Carcinoma Therapeutics -
'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE
2. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
3. Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood
4. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
5. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
6. Targeted Gold Nanoparticles and Noninvasive Radio Fields Attacking One of the Deadliest and Least Curable Types of Cancer: Pancreatic Carcinoma
7. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
8. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
9. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
10. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
11. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)...  Rosa & Co. LLC, a drug development advisory ... today announced it has two posters scheduled to be ... and Therapeutics meeting in New Orleans, LA ... - http://photos.prnewswire.com/prnh/20150302/179058LOGO   Bristol- Myers ... a quantitative systems pharmacology approach for immuno-oncology drug development ...
(Date:3/3/2015)... 03, 2015 Cambridge Semantics, the leading ... technology, today announced that it has been named to ... in Knowledge Management.’ , To create the list ... analysts and system integrators who identify organizations dedicated to ... right information to the right people at the right ...
(Date:3/3/2015)... , March 3, 2015 ... tools for implementing competency-based training to comply with new ... is offering a new crosswalk tool ... implement competency-based training for direct service workers as a ... Medicaid Services (CMS) regulations. CMS amended the ...
(Date:3/3/2015)... GlobalStemCellsGroup.com has recruited Mario ... a biomedical researcher and founding partner of Criogenix SA ... of biomedical professors who will teach the “Diplomat in ... de CV is a private company registered in the ... in Mexico (RENIECYT). , Camacho Alcocer will teach two-day, ...
Breaking Biology Technology:Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 2Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 3Cambridge Semantics Named to KMWorld’s 2015 ‘100 Companies That Matter in Knowledge Management’ 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 3Mario Camacho Alcocer Joins Global Stem Cells Group Faculty 2Mario Camacho Alcocer Joins Global Stem Cells Group Faculty 3
... 2012  Agendia, an innovative molecular cancer diagnostics company, ... contract with Blue Shield of California, making Agendia ... for future in-network coverage for MammaPrint® and other ... United States. Developed and commercialized by Agendia, MammaPrint ...
... Jan. 5, 2012 CMC Biologics, a leading ... European Patent No. US 2,171,034 B1 covering a ... mammalian cell culture bioreactors. The invention is designed ... continuous perfusion fermentation process, wherein the bioreactor (fermenter) ...
... (Nasdaq: NKTR ) President and Chief Executive Officer, ... 30th Annual J.P. Morgan Healthcare Conference in San Francisco at ... at 8:30 a.m. Pacific time. The presentation will ... the Investor Relations, Events Calendar section of the Nektar website: ...
Cached Biology Technology:Agendia Signs Contract with Blue Shield of California 2CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems 2Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA 2
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, N.C. , Feb. 5, 2015 ... as a specialist logistics company and has launched a ... industry,s only Clinical Logistics Organization (CLO).  The new campaign ... with emphasis on patient, protocol and shipments. ... Patient First , aligns Marken,s priorities with its ...
(Date:2/5/2015)... Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... RedChip Global Online CEO Conference on January 29 th ... Gino Pereira , CEO of NXT-ID will present and ... the Wocket smart wallet and its full suite of ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
... Iowa State University researchers have developed a technology that ... cervical cancer in women. Thats a significant improvement ... Edward Yeung, an Iowa State Distinguished Professor and the ... research team that developed the new test. The current ...
... percent increase in lifespan, raising the tantalizing question of ... taking an anti-aging medication. Results of the Buck Institute ... are currently published online in the Journal of Biological ... mood affective disorders, including bipolar disease for decades. While ...
... Monmouth University,s Urban Coast Institute will host its ... 2007, from 10 a.m. to 12 p.m., in the ... an Ocean Literate Society: Building Communities for Action," will ... of communication will be used to increase the general ...
Cached Biology News:Iowa State researchers develop technology for early detection of viruses 2Drug commonly used to treat bipolar disorder dramatically increases lifespan in worms 2Abel to receive posthumous Ocean and Coastal Leadership award 2
The filter 640DF35 for the Molecular Imager FX is a band pass filter for Texas Red dye....
... APO-BRDU Kit is a 2-color staining method ... DNA to detect apoptotic cells by flow ... reagents required for measuring apoptosis in cells, ... assessing reagent performance; washing, reaction and rinsing ...
The filter 530DF28 for the Molecular Imager FX is a band pass filter for ECL Plus, AttoPhos, SYBR Green, Alexa Fluor 488, FITC, Cy2, and Pro-Q Emerald dyes....
... Model 175 tube gel cell is a ... for 2-D electrophoresis applications. The upper buffer ... tubes 9-23 cm long for isoelectric focusing ... buffer chamber and cooling core, lower buffer ...
Biology Products: